MediciNova Says Considering Cost, Timing and Design of Future Trials; FDA Said Cut in Hospitalizations Should be Endpoint
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq: MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), yesterday reported financial results for the third quarter ended September 30, 2012 through the filing of its quarterly report on Form 10-Q.
On October 22, 2012 management met with the FDA to review future development of MN-221. Although discussions haven't been finalized, during the meeting the FDA identified the risk/benefit profile of MN-221 as a focal point for any further development of MN-221 and advised that a reduction in hospitalizations would need to be a pivotal trial primary endpoint. MediciNova is considering the design, costs, and timing of potential future clinical trials of MN-221 and will determine its development strategy following the completion of its review.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.